Chemotherapy is one of the fundamental modes of treatment for cancer. The treatment is based on the ability of the drugs target highly proliferative cells more efficiently than quiescent cells by disruption of either the cell cycle or proliferation signal transduction. Indeed, even though according to the cancer associations in the UK and the US Chemotherapy is part of the treatment for 10-40% and 40-85% of the stage I+II and stage III+IV patients respectively, the vast majority of the patients do not survive, mainly through the development of drug resistance.
We aim to delineate the dynamic evolution of resistance procurement by surveying and integrating the genetic, genomic and epigenomic data of different cell lines and patient samples treated with different chemotherapeutic drugs.